Fiche publication
Date publication
septembre 2026
Journal
Blood
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MAYNADIE Marc
Tous les auteurs :
Bertoli S, Landberg N, Bérard E, Gondran C, Largeaud L, Mansat-De Mas V, Dumas PY, Pigneux A, Bidet A, Garciaz S, Gabellier L, Roth Guepin G, Orvain C, Peterlin P, Birsen R, Alexis M, Carré M, Tavernier E, Boissard Simonet M, Himberlin C, Maynadié M, Laribi K, Moluçon Chabrot C, Belhabri A, Chraibi S, Cabrera Q, Lebon D, Raffoux E, Cluzeau T, Micol JB, Leclerc M, Berthon C, Dombret H, Juliusson G, Robelius A, Lehmann S, Jädersten M, Vennström L, Montesinos P, Botella C, Bergua Burgues JM, Garcia R, Serrano J, Amigo ML, García Ramirez P, Sossa-Melo CL, Alonso-Domínguez JM, Döhner H, Döhner K, Späth D, Kühn MW, Lengerke C, Tischler HJ, Röllig C, Ruhnke L, Thiede C, Burchert A, Serve H, Müller-Tidow C, Baldus CD, Versluis J, Valk PJ, Kristensen DT, Stidsholt Roug A, Mayer J, Kontro M, Ettala P, Lazarevic VL, Récher C
Lien Pubmed
Résumé
To describe the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcome of de novo BCR::ABL1+ acute myeloid leukemia (AML), we retrospectively analyzed the data of 212 adult AML with ≥20% bone marrow blasts, BCR::ABL1+ or t(9;22)(q34.1;q11.2), no history of previous chronic myeloid leukemia and no prior exposure to BCR-ABL1 TKI. Eighty-nine patients were treated with IC alone and 123 with IC+TKI between 1999 and 2024. Complete remission (CR) or CR with incomplete hematologic recovery (CRi) was achieved in 52/77 patients (68%) with IC and 110/123 patients (89%) with IC+TKI (P<0.0001). With a median follow-up of 66.7 months, the median overall survival (OS) was 20.5 months with IC and not reached with IC+TKI. The 3-year and 5-year OS rates were 42.1% and 38.5% with IC and 70.9% and 62.9% with IC+TKI (P<0.0001) respectively. In multivariate analyses, the addition of TKI to IC was significantly and independently associated with an improved CR/CRi rate (odds ratio: 4.74 [95% confidence interval: 2.17-10.35]; P<0.001) and OS (hazard ratio: 0.40 [0.27-0.62]; P<0.001). Also, adding TKI to IC and alloHSCT in CR1 were independent prognostic factors for relapse-free survival (HR: 0.42; 95% CI: 0.23-0.75; P=0.004 and HR: 0.31; 95% CI: 0.17-0.55; P<0.0001). The outcome of de novo BCR::ABL1+ AML is strongly improved by the addition of a TKI to IC and should become the standard of care. The classification as adverse-risk should be reconsidered in the future ELN classification.
Référence
Blood. 2026 09 18;:
